

Keith R Mccrae

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1120362/keith-r-mccrae-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

229
papers

6,040
citations

43
h-index

74
g-index

236
ext. papers

7,138
ext. citations

4.9
avg, IF

5.96
L-index

#	Paper	IF	Citations
229	Old is new again: Emergence of thromboembolic complications in cancer patients on immunotherapy. <i>Thrombosis Research</i> , 2022 , 213, S51-S57	8.2	1
228	Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy. <i>Targeted Oncology</i> , 2021 , 16, 813-821	5	1
227	Protection of α GPI Deficient Mice from Thrombosis May Reflect a Platelet Activation Defect. <i>Blood</i> , 2021 , 138, 2083-2083	2.2	
226	Risk of Venous Thromboembolism in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors. <i>Blood</i> , 2021 , 138, 3223-3223	2.2	
225	Abundance of B Cell Receptors Harboring Elongated Polytyrosine and Polyserine Rich Motifs within Their Heavy Chain CDR3 Distinguishes Catastrophic and Antiphospholipid Syndrome. <i>Blood</i> , 2021 , 138, 2117-2117	2.2	
224	Protective Effects of Kininogen-1 Gene Deficiency in Mouse Models of Venous Thrombosis. <i>Blood</i> , 2021 , 138, 289-289	2.2	
223	Resveratrol As a Novel Treatment for Recurrent Epistaxis in SMAD4+ Hereditary Hemorrhagic Telangiectasia. <i>Blood</i> , 2021 , 138, 1048-1048	2.2	1
222	Immune Checkpoint Inhibitors (ICI) Enhance Cancer Associated Thrombosis (CAT) in Murine Model of Colon Carcinoma. <i>Blood</i> , 2021 , 138, 779-779	2.2	0
221	Bradykinin Is a Proximal Event in Experimental Cerebral Malaria. <i>Blood</i> , 2021 , 138, 3143-3143	2.2	
220	Update to coagulopathy in COVID-19: Manifestations and management. <i>Cleveland Clinic Journal of Medicine</i> , 2021 ,	2.8	4
219	A novel "vascular" thrombophilia. <i>Blood</i> , 2021 , 137, 2133-2134	2.2	
218	Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy. <i>Med</i> , 2021 , 2, 423-434	31.7	17
217	Plasmin-mediated cleavage of high-molecular-weight kininogen contributes to acetaminophen-induced acute liver failure. <i>Blood</i> , 2021 , 138, 259-272	2.2	4
216	Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis. <i>Advances in Therapy</i> , 2021 , 38, 3113-3128	4.1	1
215	Thrombotic thrombocytopenia due to SARS-CoV-2 vaccination. <i>Cleveland Clinic Journal of Medicine</i> , 2021 ,	2.8	10
214	Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19. <i>Vascular Medicine</i> , 2021 , 26, 626-632	3.3	15
213	Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 822-829	15.4	13

212	Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, 69-80	5.1	2
211	Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival 2021 , 9,		28
210	Polyphosphate expression by cancer cell extracellular vesicles mediates binding of factor XII and contact activation. <i>Blood Advances</i> , 2021 , 5, 4741-4751	7.8	3
209	Healthcare costs of patients with cancer stratified by Khorana score risk levels. <i>Journal of Medical Economics</i> , 2021 , 24, 866-873	2.4	
208	The J-elongated conformation of β glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome. <i>Journal of Biological Chemistry</i> , 2020 , 295, 10794-10806	5.4	11
207	Factor XII and kininogen asymmetric assembly with gC1qR/C1QBP/P32 is governed by allostery. <i>Blood</i> , 2020 , 136, 1685-1697	2.2	9
206	Mechanisms and biomarkers of cancer-associated thrombosis. <i>Translational Research</i> , 2020 , 225, 33-53	11	19
205	High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2329-2340	15.4	3
204	RNA expression and risk of venous thromboembolism in lung cancer. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 117-123	5.1	4
203	Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. <i>Blood</i> , 2020 , 135, 239-251	2.2	72
202	Bleeding Outcomes of Gastrointestinal Cancer Patients Treated with Direct Oral Anticoagulants Vs. Low Molecular Weight Heparin. <i>Blood</i> , 2020 , 136, 27-27	2.2	2
201	Identification of a Warm Autoimmune Hemolytic Anemia (wAIHA) Population Using Predictive Analytics of a Known Clinically Profiled Cohort. <i>Blood</i> , 2020 , 136, 10-10	2.2	
200	Risk of Recurrent Venous Thromboembolism and Bleeding in Patients with Cancer Associated Thrombosis. <i>Blood</i> , 2020 , 136, 18-18	2.2	0
199	Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method. <i>Blood</i> , 2020 , 136, 6-8	2.2	
198	Frequency of Arterial Thromboembolic Events in Patients with Cancer Associated Venous Thromboembolism. <i>Blood</i> , 2020 , 136, 37-37	2.2	
197	Consistent Efficacy Demonstrated By Avatrombopag in Immune Thrombocytopenia (ITP) Regardless of the Number of Lines of Prior ITP Treatment. <i>Blood</i> , 2020 , 136, 32-33	2.2	
196	Epithelial-derived gasdermin D mediates nonlytic IL-1 β release during experimental colitis. <i>Journal of Clinical Investigation</i> , 2020 , 130, 4218-4234	15.9	29
195	Eculizumab for Refractory Thrombosis in Antiphospholipid Syndrome. <i>Blood</i> , 2020 , 136, 10-11	2.2	0

194	FcRn augments induction of tissue factor activity by IgG-containing immune complexes. <i>Blood</i> , 2020 , 135, 2085-2093	2.2	11
193	Coagulopathy in COVID-19: Manifestations and management. <i>Cleveland Clinic Journal of Medicine</i> , 2020 , 87, 461-468	2.8	40
192	Outcomes of Cardiovascular Surgery Utilizing Heparin versus Direct Thrombin Inhibitors in Cardiopulmonary Bypass in Patients with Previously Diagnosed HIT. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 300-305	7	3
191	Clinical outcomes of isolated distal deep vein thrombosis versus proximal venous thromboembolism in cancer patients: The Cleveland Clinic experience. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 651-659	15.4	13
190	Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer. <i>Journal of Medical Economics</i> , 2020 , 23, 323-329	2.4	3
189	SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. <i>EBioMedicine</i> , 2020 , 58, 102907	8.8	75
188	Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels. <i>Cancer Medicine</i> , 2020 , 9, 8062-8073	4.8	7
187	Report of a 'consensus' on the lines of therapy for primary immune thrombocytopenia in adults, promoted by the Italian Gruppo di Studio delle Piastrine. <i>Platelets</i> , 2020 , 31, 461-473	3.6	1
186	"HIT"ing back against NETs. <i>Blood</i> , 2020 , 135, 706-707	2.2	2
185	A non-circulating pool of factor XI associated with glycosaminoglycans in mice. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 1449-1460	15.4	4
184	Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants. <i>Journal of Medical Economics</i> , 2019 , 22, 1134-1140	2.4	7
183	Bleeding incidence and risk factors among cancer patients treated with anticoagulation. <i>American Journal of Hematology</i> , 2019 , 94, 780-785	7.1	29
182	Plasma kallikrein structure reveals apple domain disc rotated conformation compared to factor XI. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 759-770	15.4	15
181	Complement in the Pathophysiology of the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2019 , 10, 449	8.4	50
180	Duration of anticoagulant therapy and VTE recurrence in patients with cancer. <i>Supportive Care in Cancer</i> , 2019 , 27, 3833-3840	3.9	5
179	Phase II study of Dovitinib in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019 , 144, 359-368	4.8	16
178	Molecular Subtyping to Predict Risk of Venous Thromboembolism in Patients with Advanced Lung Adenocarcinoma: A Cohort Study. <i>Blood</i> , 2019 , 134, 3651-3651	2.2	2
177	Biomarker Assessment of Venous Thromboembolism in Cancer Patients Receiving Checkpoint Blockade. <i>Blood</i> , 2019 , 134, 3648-3648	2.2	2

176	The Burden of Disease and IMPACT of Immune Thrombocytopenia (ITP) on Patients: Results from an ITP Survey. <i>Blood</i> , 2019 , 134, 1076-1076	2.2	2
175	Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations. <i>Blood</i> , 2019 , 134, 90-90	2.2	1
174	Mice Deficient in α -Glycoprotein I Have a Delayed Time to Thrombosis. <i>Blood</i> , 2019 , 134, 2423-2423	2.2	1
173	Pomalidomide Reduces Bleeding and Alters Expression of Angiogenesis-Related Proteins in Patients with Hereditary Hemorrhagic Telangiectasia. <i>Blood</i> , 2019 , 134, 5761-5761	2.2	
172	Rare Germline Mutations in Complement Regulatory Genes Make the Antiphospholipid Syndrome Catastrophic. <i>Blood</i> , 2019 , 134, 4-4	2.2	1
171	Cancer Associated Thrombosis Is Associated with Higher Mortality across All Khorana Score Risk Levels. <i>Blood</i> , 2019 , 134, 1143-1143	2.2	
170	Characterization of Recombinant α GPI Using Hydrogen-Deuterium Exchange and X-Ray Crystallography. <i>Blood</i> , 2019 , 134, 1105-1105	2.2	
169	Identifying miRNA Biomarkers and Predicted Targets Associated with Venous Thromboembolism in Colorectal Cancer Patients. <i>Blood</i> , 2019 , 134, 3643-3643	2.2	0
168	High Molecular Weight Kininogen but Not Factor XII Deficiency Attenuates Acetaminophen-Induced Liver Injury in Mice. <i>Blood</i> , 2019 , 134, 3621-3621	2.2	
167	Clinical Outcomes of Cancer-Associated Thrombosis Beyond 6 Months of Anticoagulation. <i>Blood</i> , 2019 , 134, 3458-3458	2.2	3
166	African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2019 , 134, 1066-1066	2.2	
165	American Society of Hematology 2019 guidelines for immune thrombocytopenia. <i>Blood Advances</i> , 2019 , 3, 3829-3866	7.8	299
164	Prognostic Value of Preoperative Red Cell Distribution Width: Fine-Tuning by Mean Corpuscular Volume. <i>Annals of Thoracic Surgery</i> , 2019 , 108, 1830-1838	2.7	3
163	A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain. <i>Blood</i> , 2019 , 133, 1152-1163	2.2	29
162	The risk of recurrent VTE and major bleeding in a commercially-insured population of cancer patients treated with anticoagulation. <i>American Journal of Hematology</i> , 2019 , 94, E58-E61	7.1	8
161	Kininogen deficiency or depletion reduces enhanced pause independent of pulmonary inflammation in a house dust mite-induced murine asthma model. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2019 , 316, L187-L196	5.8	1
160	Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. <i>American Journal of Hematology</i> , 2018 , 93, 664-671	7.1	54
159	Splenectomy for immune thrombocytopenia: down but not out. <i>Blood</i> , 2018 , 131, 1172-1182	2.2	86

158	Effects of anti- α GPI antibodies on VWF release from human umbilical vein endothelial cells and ADAMTS13 activity. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018 , 2, 380-389	5.1	7
157	Extracellular Vesicles in the Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018 , 44, 493-504	5.3	16
156	Clinical Outcomes with Direct Oral Anticoagulants Compared to Low Molecular Weight Heparins in the Treatment of Cancer-Associated Venous Thromboembolism. <i>Blood</i> , 2018 , 132, 1237-1237	2.2	2
155	The Rate of Venous Thromboembolism in Cancer Patients Varies By Khorana Risk Category. <i>Blood</i> , 2018 , 132, 3798-3798	2.2	1
154	High Molecular Weight Kininogen Contributes to End-Organ Damage and Mortality in a Mouse Model of Sickle Cell Disease. <i>Blood</i> , 2018 , 132, 268-268	2.2	1
153	Healthcare Costs in Patients with Cancer Increase with Increasing Risk of Venous Thromboembolism. <i>Blood</i> , 2018 , 132, 3799-3799	2.2	1
152	An answer to "anticoagulant treatment of cancer-associated venous thromboembolism: Interpreting real-world data with caution". <i>American Journal of Hematology</i> , 2018 , 93, E225-E227	7.1	
151	Expression of Recombinant α GPI and Site-Directed Mutants Provides Insight into the Pathogenesis of Antiphospholipid Syndrome. <i>Blood</i> , 2018 , 132, 1226-1226	2.2	
150	The Role of High Molecular Weight Kininogen in Lymphoma Microvascular Density and Growth. <i>Blood</i> , 2018 , 132, 1591-1591	2.2	
149	Deaths Due to Thrombotic Versus Bleeding Events within 90 Days of Cancer Associated Thrombosis. <i>Blood</i> , 2018 , 132, 3570-3570	2.2	
148	Exosome Polyphosphate Mediates the Activation of FXII By Cancer Cell-Derived Exosomes. <i>Blood</i> , 2018 , 132, 3800-3800	2.2	
147	Clinical Outcomes of Isolated Distal Deep Vein Thrombosis Associated with Cancer: The Cleveland Clinic Experience. <i>Blood</i> , 2018 , 132, 4809-4809	2.2	
146	Heparin Vs Direct Thrombin Inhibitors in Patients with Previous HIT Undergoing Cardiothoracic Surgery: The Cleveland Clinic Experience. <i>Blood</i> , 2018 , 132, 425-425	2.2	
145	Limited role of kininogen in the host response during gram-negative pneumonia-derived sepsis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2018 , 314, L397-L405	5.8	11
144	Preoperative Anemia in Cardiac Operation: Does Hemoglobin Tell the Whole Story?. <i>Annals of Thoracic Surgery</i> , 2018 , 105, 100-107	2.7	23
143	Factor XII Activation Promotes Platelet Consumption in the Presence of Bacterial-Type Long-Chain Polyphosphate In Vitro and In Vivo. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018 , 38, 1748-1760 ⁴	9.4	21
142	Post-traumatic stress disorder and depression in survivors of thrombotic thrombocytopenic purpura. <i>Thrombosis Research</i> , 2017 , 151, 51-56	8.2	19
141	Depression and post-traumatic stress disorder in individuals with hereditary hemorrhagic telangiectasia: A cross-sectional survey. <i>Thrombosis Research</i> , 2017 , 153, 14-18	8.2	6

140	Predicting risk of venous thromboembolism in hospitalized cancer patients: Utility of a risk assessment tool. <i>American Journal of Hematology</i> , 2017 , 92, 501-507	7.1	46
139	Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017 , 1, 14-22	5.1	65
138	Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2017 , 92, 730-738	7.1	32
137	Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort Study. <i>JNCI Cancer Spectrum</i> , 2017 , 1, pxx009	4.6	2
136	CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors. <i>Journal of Experimental Medicine</i> , 2017 , 214, 2715-2732	16.6	43
135	Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers. <i>Current Rheumatology Reports</i> , 2017 , 19, 43	4.9	9
134	Diagnosis and management of the antiphospholipid syndrome. <i>Blood Reviews</i> , 2017 , 31, 406-417	11.1	71
133	Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. <i>Cancer Research</i> , 2016 , 76, 3671-5	10.1	23
132	A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation. <i>Thrombosis Research</i> , 2016 , 140, 118-124	8.2	43
131	Recurrent venous thromboembolism in glioblastoma. <i>Thrombosis Research</i> , 2016 , 137, 184-188	8.2	31
130	Safety of Anticoagulant Therapies for Treatment of Venous Thromboembolism in Patients with Cancer. <i>Blood</i> , 2016 , 128, 1178-1178	2.2	2
129	Regulation of the Tumor Microenvironment By High Molecular Weight Kininogen. <i>Blood</i> , 2016 , 128, 1394-1394	2.2	2
128	Pomalidomide in Hereditary Hemorrhagic Telangiectasia: Interim Results of a Phase I Study. <i>Blood</i> , 2016 , 128, 210-210	2.2	6
127	VTE-Related Healthcare Resource Utilization and Costs Associated with Venous Thromboembolism in Cancer Patients Treated with Anticoagulants. <i>Blood</i> , 2016 , 128, 3524-3524	2.2	1
126	Recombinant α -Glycoprotein I (α GPI) Produced Using a Novel Lentiviral Approach Functions at Least As Well As Plasma-Derived α GPI in Detection of Anti- α GPI Antibodies. <i>Blood</i> , 2016 , 128, 2596-2596	2.2	2
125	Anti- α GPI Antibodies Induce Oxidative and Nitrate Stress in Endothelial Cells through Activation of Discrete Nox Isoforms and eNOS Uncoupling. <i>Blood</i> , 2016 , 128, 720-720	2.2	
124	Healthcare Resource Utilization and Costs Associated with Venous Thromboembolism Recurrence in Patients with Cancer. <i>Blood</i> , 2016 , 128, 4734-4734	2.2	
123	Post Traumatic Stress Disorder and Depression in Survivors of Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2016 , 128, 1364-1364	2.2	

122	Predictors of recurrent venous thromboembolism and bleeding on anticoagulation. <i>Thrombosis Research</i> , 2016 , 140 Suppl 1, S93-8	8.2	17
121	Treatment of chronic immune thrombocytopenia in children with romiplostim. <i>Lancet, The</i> , 2016 , 388, 4-6	4.0	3
120	Fc β III in ITP: it ain't over 'til it's over. <i>Blood</i> , 2016 , 127, 11-2	2.2	1
119	Novel role for p56/Lck in regulation of endothelial cell survival and angiogenesis. <i>FASEB Journal</i> , 2016 , 30, 3515-3526	0.9	10
118	Centralizing care of cancer-associated thromboembolism: The Cleveland Clinic experience. <i>Thrombosis Research</i> , 2016 , 147, 102-103	8.2	7
117	Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed?. <i>Thrombosis Research</i> , 2016 , 145, 51-3	8.2	95
116	Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions. <i>Journal of Allergy and Clinical Immunology</i> , 2015 , 135, 1031-1043.e6	11.5	90
115	Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations. <i>Thrombosis Research</i> , 2015 , 135, 102-8	8.2	28
114	Increased morbidity during long-term follow-up of survivors of thrombotic thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2015 , 90, E208	7.1	13
113	Over-testing for heparin induced thrombocytopenia in hospitalized patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 40, 12-6	5.1	18
112	Lipocalin-2 released in response to cerebral ischaemia mediates reperfusion injury in mice. <i>Journal of Cellular and Molecular Medicine</i> , 2015 , 19, 1637-45	5.6	42
111	The antiphospholipid syndrome: still an enigma. <i>Hematology American Society of Hematology Education Program</i> , 2015 , 2015, 53-60	3.1	29
110	Improving Outcomes and Reducing Costs for Cancer Associated Thrombosis Using a Centralized Service: The Cleveland Clinic Experience. <i>Blood</i> , 2015 , 126, 1122-1122	2.2	1
109	A History of Abnormal Bleeding Correlates with Platelet Dysfunction in Aggregation Studies but Not PFA-100 Analyses. <i>Blood</i> , 2015 , 126, 3447-3447	2.2	1
108	Current Practice Patterns and Patient Persistence on Anticoagulant Treatments for Cancer-Associated Thrombosis. <i>Blood</i> , 2015 , 126, 626-626	2.2	6
107	Platelet Function Testing Is Commonly Performed in Patients with Known Confounding Factors. <i>Blood</i> , 2015 , 126, 4726-4726	2.2	
106	Suboptimal Antiplatelet Therapy Suggested By Platelet Aggregation Studies Does Not Correlate with a Change in Clinical Management. <i>Blood</i> , 2015 , 126, 4634-4634	2.2	
105	Impact of a Cancer Associated Thrombosis Clinic on Reducing Hospitalization for Venous Thromboembolism: The Cleveland Clinic Experience. <i>Blood</i> , 2015 , 126, 5588-5588	2.2	

104	NADPH Oxidase Activation and Endothelial Nitric Oxide Synthase Uncoupling Contribute to Endothelial Dysfunction in Antiphospholipid Syndrome. <i>Blood</i> , 2015 , 126, 4639-4639	2.2	
103	Diastolic but Not Systolic Heart Failure Is Associated with Multiple Abnormalities on Platelet Aggregation Testing. <i>Blood</i> , 2015 , 126, 1079-1079	2.2	
102	Extracellular Vesicles Derived from HT-29 Colorectal Cancer Cells Induce Endothelial Cell Activation and Procoagulant Activity. <i>Blood</i> , 2015 , 126, 3456-3456	2.2	
101	Risk stratification strategies for cancer-associated thrombosis: an update. <i>Thrombosis Research</i> , 2014 , 133 Suppl 2, S35-8	8.2	76
100	Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer. <i>PLoS ONE</i> , 2014 , 9, e94048	3.7	31
99	Rituximab for treatment of inhibitors in haemophilia A. A Phase II study. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 445-58	7	34
98	Antiplatelet antibodies in oxaliplatin-induced immune thrombocytopenia. <i>JRSM Open</i> , 2014 , 5, 20542704145315126	4.1	15
97	High-relaxivity superparamagnetic iron oxide nanoworms with decreased immune recognition and long-circulating properties. <i>ACS Nano</i> , 2014 , 8, 12437-49	16.7	48
96	Recent advances in the antiphospholipid antibody syndrome. <i>Current Opinion in Hematology</i> , 2014 , 21, 371-9	3.3	18
95	CD14 and Tissue Factor Positive Extracellular Vesicles Predict Response to Dovitinib in Patients with GBM: A Pilot Study. <i>Blood</i> , 2014 , 124, 4999-4999	2.2	
94	Increased Morbidity during Long Term Follow up of Survivors of Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2014 , 124, 230-230	2.2	
93	Therapy with Bevacizumab Is Associated with Reduced Expression of KLF2 in Peripheral Blood Mononuclear Cells: A Potential Prothrombotic Mechanism. <i>Blood</i> , 2014 , 124, 4254-4254	2.2	1
92	A Novel Mechanism of Cellular Activation Mediated By Antiphospholipid Antibody-Induced Extracellular Vesicles. <i>Blood</i> , 2014 , 124, 100-100	2.2	
91	Risk of Arterial and Venous Thrombosis in Patients with Indeterminate Lupus Anticoagulant Testing. <i>Blood</i> , 2014 , 124, 4249-4249	2.2	
90	The SRC Kinase Family Member Lymphocyte Specific Kinase (p56Lck) Regulates Endothelial Cell Proliferation and Survival. <i>Blood</i> , 2014 , 124, 1445-1445	2.2	
89	The Day 1 Postoperative Platelet Count Predicts Splenectomy Response in Patients with Immune Thrombocytopenia (ITP). <i>Blood</i> , 2014 , 124, 1448-1448	2.2	
88	NADPH Oxidase Mediates Antiphospholipid Antibody-Induced Endothelial Cell Activation. <i>Blood</i> , 2014 , 124, 1447-1447	2.2	
87	Long Term Outcomes of Warm and Cold Antibody-Mediated Autoimmune Hemolytic Anemia Treated with Rituximab from a 13 Year Retrospective Cohort. <i>Blood</i> , 2014 , 124, 4009-4009	2.2	

86	Post Operative Thrombosis Among Patients Testing Indeterminate for Lupus Anticoagulant. <i>Blood</i> , 2014 , 124, 4255-4255	2.2	
85	Anti- β -GPI Antibodies Induce Von Willebrand Factor Release, Modulate Platelet Binding, and Affect VWF Proteolysis. <i>Blood</i> , 2014 , 124, 1444-1444	2.2	
84	Management and outcomes for patients with TTP: analysis of 100 cases at a single institution. <i>American Journal of Hematology</i> , 2013 , 88, 560-5	7.1	23
83	Immune thrombocytopenia. <i>Hematology/Oncology Clinics of North America</i> , 2013 , 27, 495-520	3.1	102
82	Restoration of glycemic control in patients with type 2 diabetes mellitus after bariatric surgery is associated with reduction in microparticles. <i>Surgery for Obesity and Related Diseases</i> , 2013 , 9, 207-12	3	31
81	Approaches to synthetic platelet analogs. <i>Biomaterials</i> , 2013 , 34, 526-41	15.6	73
80	Anti- β GPI antibodies stimulate endothelial cell microparticle release via a nonmuscle myosin II motor protein-dependent pathway. <i>Blood</i> , 2013 , 122, 3808-17	2.2	25
79	A Proteomics-Based Approach To Identifying Mechanisms Of Cancer-Associated Thrombosis: Potential Role For Immunoglobulins. <i>Blood</i> , 2013 , 122, 1127-1127	2.2	2
78	Thirteen Year Retrospective Analysis Of Adult Patients With Autoimmune Hemolytic Anemia At The Cleveland Clinic: Diagnosis and Prevalence Of Associated Disorders. <i>Blood</i> , 2013 , 122, 955-955	2.2	1
77	Detectable Or Normal ADAMTS13 Activity In Patients Presenting With Thrombotic Thrombocytopenic Purpura (TTP) Is Associated With Poor Renal Outcomes. <i>Blood</i> , 2013 , 122, 4752-4752 ^{2,2}		
76	The Effect Of Insurance Status and Comorbidities On Outcomes After Splenectomy Among Patients With ITP. <i>Blood</i> , 2013 , 122, 3560-3560	2.2	
75	Antiphospholipid Antibodies Increase Von Willebrand Factor-Platelet String Formation From Human Endothelial Cells Under Physiologic Flow Conditions. <i>Blood</i> , 2013 , 122, 2305-2305	2.2	
74	Antiphospholipid Antibodies Stimulate Release Of Endothelial Cell Microparticles Enriched In IL-1 β <i>Blood</i> , 2013 , 122, 35-35	2.2	
73	Thirteen Year Retrospective Analysis Of Adult Patients With Autoimmune Hemolytic Anemia At The Cleveland Clinic: Responses To Therapy. <i>Blood</i> , 2013 , 122, 3423-3423	2.2	
72	A novel pathway for human endothelial cell activation by antiphospholipid/anti- β glycoprotein I antibodies. <i>Blood</i> , 2012 , 119, 884-93	2.2	102
71	Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation. <i>Blood</i> , 2012 , 120, 4082-92	2.2	99
70	Chimeric glutathione S-transferases containing inserts of kininogen peptides: potential novel protein therapeutics. <i>Journal of Biological Chemistry</i> , 2012 , 287, 22142-50	5.4	2
69	Induction of Endothelial Cell Apoptosis by Cleaved High Molecular Weight Kininogen Is Mediated Through a Lck and p53-Dependent Pathway. <i>Blood</i> , 2012 , 120, 3305-3305	2.2	

68	Thrombotic Thrombocytopenic Purpura At the Cleveland Clinic 2000-2012: Review of 100 Cases and Identification of Prognostic Factors. <i>Blood</i> , 2012 , 120, 3325-3325	2.2	1
67	Analysis of Changes in Endothelial Cell Protein Expression and Phosphorylation Induced by Cleaved High Molecular Weight Kininogen. <i>Blood</i> , 2012 , 120, 5195-5195	2.2	
66	Immune thrombocytopenia: no longer 'idiopathic'. <i>Cleveland Clinic Journal of Medicine</i> , 2011 , 78, 358-73	2.8	44
65	Endothelial cell activation by antiphospholipid antibodies is modulated by Kruppel-like transcription factors. <i>Blood</i> , 2011 , 117, 6383-91	2.2	31
64	Sutton's law and anti-β2GPI antibodies. <i>Blood</i> , 2011 , 117, 3253-5	2.2	
63	Angiogenesis and Tumor Growth Are Increased in Kininogen Deficient Mice. <i>Blood</i> , 2011 , 118, 371-371	2.2	
62	KLF2 and KLF4 Are Essential Mediators of the Anti-Thrombotic Effects of Statins in the Presence of Antiphospholipid/Anti-β2GPI Antibodies. <i>Blood</i> , 2011 , 118, 3272-3272	2.2	
61	Non-Muscle Myosin II Mediates Microparticle Release From Endothelial Cells Activated by Antiphospholipid Antibodies. <i>Blood</i> , 2011 , 118, 3343-3343	2.2	
60	Dose of prophylactic platelet transfusions and prevention of hemorrhage. <i>New England Journal of Medicine</i> , 2010 , 362, 600-13	59.2	440
59	Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis. <i>Blood</i> , 2010 , 115, 5111-20	2.2	91
58	Impaired fibrinolysis in the antiphospholipid syndrome. <i>Current Rheumatology Reports</i> , 2010 , 12, 53-7	4.9	60
57	Bortezomib for ITP: First Report of Successful Treatment of Refractory ITP In a Patient with Otherwise Asymptomatic Monoclonal Gammopathy. <i>Blood</i> , 2010 , 116, 4667-4667	2.2	2
56	Antiphospholipid/Anti-β2GPI Antibodies Induce Endothelial Cell Activation through Formation of a Multi-Protein Signaling Complex Consisting of Annexin A2, Toll-Like Receptor 4, Calreticulin and Nucleolin. <i>Blood</i> , 2010 , 116, 151-151	2.2	
55	Decreased Expression of KLF2 and KLF4 Induced by Antiphospholipid Antibodies Promotes NF-Kb-Mediated Endothelial Cell Activation and Is Modulated by CBP/p300. <i>Blood</i> , 2010 , 116, 4315-4315 ^{2.2}	2.2	
54	Noonan syndrome/leukemia-associated gain-of-function mutations in SHP-2 phosphatase (PTPN11) enhance cell migration and angiogenesis. <i>Journal of Biological Chemistry</i> , 2009 , 284, 913-20	5.4	32
53	A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. <i>Clinical Cancer Research</i> , 2009 , 15, 3583-90	12.9	84
52	Contact activation of kallikrein-kinin system by superparamagnetic iron oxide nanoparticles in vitro and in vivo. <i>Journal of Controlled Release</i> , 2009 , 140, 301-5	11.7	31
51	beta2-glycoprotein I is a cofactor for tissue plasminogen activator-mediated plasminogen activation. <i>Arthritis and Rheumatism</i> , 2009 , 60, 559-68		38

50	Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. <i>Biomaterials</i> , 2009 , 30, 3926-33	15.6	131
49	Acute profound thrombocytopenia with second exposure to eptifibatid associated with a strong antibody reaction. <i>Platelets</i> , 2009 , 20, 64-7	3.6	10
48	Factor XII Stimulates ERK1/2 and Akt through uPAR, Integrins, and the EGFR to Initiate Angiogenesis.. <i>Blood</i> , 2009 , 114, 3040-3040	2.2	
47	Von Willebrand disease: screening, diagnosis, and management. <i>Aesthetic Surgery Journal</i> , 2008 , 28, 189-94	2.4	15
46	Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. <i>Blood</i> , 2008 , 111, 1274-81	2.2	111
45	Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. <i>Journal of Clinical Investigation</i> , 2008 , 118, 1934-43	15.9	118
44	Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin. <i>Clinical Cancer Research</i> , 2007 , 13, 5862-8	12.9	44
43	Immune thrombocytopenic purpura in pregnancy. <i>Current Opinion in Hematology</i> , 2007 , 14, 574-80	3.3	39
42	Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. <i>Current Opinion in Hematology</i> , 2007 , 14, 468-80	3.3	27
41	Endothelial Derived Microparticles Bind and Activate Platelets in a CD36 Dependent Manner.. <i>Blood</i> , 2007 , 110, 418-418	2.2	
40	Quantitative Analysis of Angiogenesis Inhibition by Cleaved High Molecular Weight Kininogen Using VESGEN.. <i>Blood</i> , 2007 , 110, 3907-3907	2.2	
39	α-Glycoprotein I Is a Cofactor for t-PA-Mediated Plasminogen Activation.. <i>Blood</i> , 2007 , 110, 404-404	2.2	
38	Microparticles as a Predictor of Acute Deep Venous Thrombosis in a Patient with Antiphospholipid Antibody Syndrome.. <i>Blood</i> , 2007 , 110, 3984-3984	2.2	
37	Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. <i>Journal of Virology</i> , 2006 , 80, 4833-46	6.6	102
36	Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1485-8	2.2	54
35	Endothelial-cell apoptosis induced by cleaved high-molecular-weight kininogen (HKa) is matrix dependent and requires the generation of reactive oxygen species. <i>Blood</i> , 2006 , 107, 4714-20	2.2	17
34	Annexin and APS: the clot thickens. <i>Blood</i> , 2006 , 107, 4195-4196	2.2	2
33	Definition of the Apoptotic Pathway Induced in Proliferating Endothelial Cells by Cleaved High Molecular Weight Kininogen.. <i>Blood</i> , 2006 , 108, 3937-3937	2.2	

32	Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. <i>Blood</i> , 2005 , 105, 1964-9	2.2	178
31	A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck. <i>Cancer Chemotherapy and Pharmacology</i> , 2005 , 55, 295-300	3.5	39
30	Inhibition of angiogenesis by cleaved high molecular weight kininogen (HKa) and HKa domain 5. <i>Current Cancer Drug Targets</i> , 2005 , 5, 519-28	2.8	10
29	Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. <i>Clinical Cancer Research</i> , 2005 , 11, 7938-44	12.9	43
28	Histidine-proline rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells. <i>Thrombosis and Haemostasis</i> , 2004 , 92, 403-12	7	41
27	Helicobacter pylori and ITP: many questions, few answers. <i>Blood</i> , 2004 , 103, 752-753	2.2	10
26	Activation of Endothelial Cells by β -Glycoprotein I (β GPI) Antibodies Is Mediated by Annexin II Cross Linking and May Involve TLR4.. <i>Blood</i> , 2004 , 104, 278-278	2.2	8
25	Extracellular tropomyosin: a novel common pathway target for anti-angiogenic therapy. <i>Current Cancer Drug Targets</i> , 2004 , 4, 543-53	2.8	12
24	Apoptosis of Proliferating Endothelial Cells Induced by Cleaved High Molecular Weight Kininogen (HKa) Involves an Oxidation-Dependent Pathway.. <i>Blood</i> , 2004 , 104, 3926-3926	2.2	
23	Characterization of the Interaction between Cleaved High Molecular Weight Kininogen (HKa) and Tropomyosin (TM) on Endothelial Cells.. <i>Blood</i> , 2004 , 104, 3918-3918	2.2	1
22	Splenectomy in immune thrombocytopenic purpura: recent controversies and long-term outcomes. <i>Psychophysiology</i> , 2004 , 3, 317-23		8
21	Thrombocytopenia in pregnancy: differential diagnosis, pathogenesis, and management. <i>Blood Reviews</i> , 2003 , 17, 7-14	11.1	82
20	Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. <i>American Journal of Pathology</i> , 2003 , 163, 1193-200	5.8	136
19	Arterial thrombosis in a gynecologic oncology patient: evaluation and management. <i>Gynecologic Oncology</i> , 2002 , 87, 228-30	4.9	3
18	The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 12224-9	11.5	51
17	Inhibition of angiogenesis by two-chain high molecular weight kininogen (HKa) and kininogen-derived polypeptides. <i>Canadian Journal of Physiology and Pharmacology</i> , 2002 , 80, 85-90	2.4	16
16	Successful management of life-threatening hemorrhage in a patient with synchronous lupus anticoagulant and factor VIII inhibitor. <i>Journal of Vascular Surgery</i> , 2002 , 36, 853-5	3.5	12
15	A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. <i>Cancer Research</i> , 2002 , 62, 3408-16	10.1	281

14	Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain. <i>Cancer Research</i> , 2002 , 62, 5344-50	10.1	61
13	Regulation of the ligand binding activity of the human very low density lipoprotein receptor by protein kinase C-dependent phosphorylation. <i>Journal of Biological Chemistry</i> , 2001 , 276, 555-62	5.4	10
12	High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II. <i>Journal of Biological Chemistry</i> , 2000 , 275, 15541-8	5.4	175
11	Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. <i>FASEB Journal</i> , 2000 , 14, 2589-600	0.9	101
10	SV40 Tag transformation of the normal invasive trophoblast results in a premalignant phenotype. I. Mechanisms responsible for hyperinvasiveness and resistance to anti-invasive action of TGFbeta. <i>International Journal of Cancer</i> , 1998 , 77, 429-39	7.5	48
9	The low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor regulates cell surface plasminogen activator activity on human trophoblast cells. <i>Journal of Biological Chemistry</i> , 1998 , 273, 32273-80	5.4	34
8	Physical and biological significance of peptide sequences mediating the interaction between high molecular weight kininogen and plasma prekallikrein. <i>Immunopharmacology</i> , 1997 , 36, 193-200		
7	Posttransfusion purpura: two unusual cases and a literature review. <i>American Journal of Hematology</i> , 1996 , 52, 205-11	7.1	22
6	The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes. <i>Journal of Biological Chemistry</i> , 1995 , 270, 26550-7	5.4	112
5	Molecular mechanisms controlling trophoblast invasion of the uterus. <i>Placenta</i> , 1993 , 14, 237-250	3.4	3
4	Plasma concentration of endothelin-1 in women with cocaine-associated pregnancy complications. <i>American Journal of Obstetrics and Gynecology</i> , 1993 , 168, 528-33	6.4	24
3	Localization of transforming growth factor-beta at the human fetal-maternal interface: role in trophoblast growth and differentiation. <i>Biology of Reproduction</i> , 1992 , 46, 561-72	3.9	325
2	Detection of endothelial cell-reactive immunoglobulin in patients with anti-phospholipid antibodies. <i>British Journal of Haematology</i> , 1991 , 79, 595-605	4.5	93
1	A novel inhibitor of steroid biosynthesis. <i>Journal of the American Chemical Society</i> , 1978 , 100, 4900-4902	16.4	34